BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 36901916)

  • 21. Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.
    Yang L; Huang F; Mei J; Wang X; Zhang Q; Wang H; Xi M; You Z
    Int J Gynecol Cancer; 2017 Feb; 27(2):196-205. PubMed ID: 27870715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands.
    Karasar P; Esendagli G
    Breast Cancer Res Treat; 2014 Jun; 145(3):605-14. PubMed ID: 24816762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
    Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
    Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.
    Ács B; Madaras L; Tőkés AM; Kovács AK; Kovács E; Ozsvári-Vidákovich M; Karászi Á; Birtalan E; Dank M; Szász AM; Kulka J
    Breast; 2017 Oct; 35():69-77. PubMed ID: 28651116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
    Xu Y; Wu Y; Zhang S; Ma P; Jin X; Wang Z; Yao M; Zhang E; Tao B; Qin Y; Chen H; Liu A; Chen M; Xiao M; Lu C; Mao R; Fan Y
    Cell Rep; 2019 Dec; 29(11):3435-3447.e4. PubMed ID: 31825827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.
    Stevenson VB; Perry SN; Todd M; Huckle WR; LeRoith T
    Vet Pathol; 2021 Jul; 58(4):692-698. PubMed ID: 34169800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development.
    Hosseinkhani N; Hemmat N; Baghbani E; Baghbanzadeh A; Kazemi T; Mokhtarzadeh A; Jafarlou M; Amin Doustvandi M; Baradaran B
    Gene; 2024 Feb; 896():148043. PubMed ID: 38042220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
    Karpathiou G; Chauleur C; Mobarki M; Peoc'h M
    Pathol Res Pract; 2020 Jan; 216(1):152782. PubMed ID: 31862202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
    Álvarez-Sierra D; Marín-Sánchez A; Ruiz-Blázquez P; de Jesús Gil C; Iglesias-Felip C; González Ó; Casteras A; Costa RF; Nuciforo P; Colobran R; Pujol-Borrell R
    J Autoimmun; 2019 Sep; 103():102285. PubMed ID: 31182340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor cell-intrinsic CD274/PD-L1: A novel metabolic balancing act with clinical potential.
    Clark CA; Gupta HB; Curiel TJ
    Autophagy; 2017 May; 13(5):987-988. PubMed ID: 28368722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profiling targetable immune checkpoints in osteosarcoma.
    McEachron TA; Triche TJ; Sorenson L; Parham DM; Carpten JD
    Oncoimmunology; 2018; 7(12):e1475873. PubMed ID: 30524885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells.
    Dietz LL; Furman NT; Larsen TV; Daugaard TF; Thomsen EA; Keller JL; Aagaard L; Sorensen BS; Nielsen AL
    J Immunother; 2022 Nov-Dec 01; 45(9):379-388. PubMed ID: 36036966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.
    Kawaguchi K; Suzuki E; Yamaguchi A; Yamamoto M; Morita S; Toi M
    Breast Cancer; 2017 Jan; 24(1):111-120. PubMed ID: 26942414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
    Kong T; Ahn R; Yang K; Zhu X; Fu Z; Morin G; Bramley R; Cliffe NC; Xue Y; Kuasne H; Li Q; Jung S; Gonzalez AV; Camilleri-Broet S; Guiot MC; Park M; Ursini-Siegel J; Huang S
    Cancer Res; 2020 Feb; 80(3):444-457. PubMed ID: 31722999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC.
    Fernandez AI; Gavrielatou N; McCann L; Shafi S; Moutafi MK; Martinez-Morilla S; Vathiotis IA; Aung TN; Yaghoobi V; Bai Y; Chan YG; Weidler J; Herbst R; Bates M; Rimm DL
    J Thorac Oncol; 2022 Sep; 17(9):1078-1085. PubMed ID: 35764237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
    Coombs MRP; Harrison ME; Hoskin DW
    Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment.
    Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.